Comparison tool
Compare peptides
Pick up to three compounds. Useful for deciding whether two peptides in a stack actually do different things, or whether you're paying twice for the same pathway.
Select up to three (2/3)
Comparison results
| Attribute | ||
|---|---|---|
| Category | Recovery & repair | Recovery & repair |
| Evidence grade | Emerging | Emerging |
| Also known as | Body Protection Compound 157, PL 14736 | Thymosin Beta-4 fragment, TB4 |
| Mechanism | Appears to upregulate growth-hormone receptor expression in tendon fibroblasts and promote angiogenesis via the VEGFR2–Akt–eNOS pathway, accelerating the formation of new blood vessels at an injury site. It also modulates nitric oxide signalling and appears protective of the gut lining. | Binds G-actin and promotes actin polymerisation, which drives cell migration into damaged tissue. It also stimulates endothelial cell differentiation and new capillary growth, and downregulates inflammatory cytokines. |
| Key benefits | Faster tendon, ligament and muscle healing in rodent models · Protective effect on the gastrointestinal lining, including NSAID-induced damage · Reduced local inflammation around injury sites · Anecdotal relief from tendinopathy and joint pain | Improved cell migration and wound closure in animal studies · Reported flexibility gains and reduced muscle spasm · Systemic action rather than site-specific, unlike BPC-157 |
| Side effects | Injection-site irritation · Transient dizziness or nausea · Unknown long-term safety profile | Fatigue or head-rush after dosing · Injection-site reaction · Theoretical tumour-growth concern given angiogenic activity |
| Half-life | Approximately 4 hours (stable oral form debated) | Roughly 2–3 hours, with tissue effects lasting far longer |
| Administration | Subcutaneous injection; oral capsules used for gut-specific goals | Subcutaneous or intramuscular injection |
| Dosing overview | Commonly cited in literature at 200–500 mcg once or twice daily for 4–8 weeks | Loading phase of 2–5 mg twice weekly for 4–6 weeks, then a lower maintenance dose |
| Storage | Lyophilised powder refrigerated; reconstituted vials 2–8 °C, used within ~30 days | Powder at room temperature short term; reconstituted 2–8 °C for up to 30 days |
| Legal status | Not FDA-approved. Research-chemical status in most countries; prohibited in sport. | Not approved for human use; sold for research purposes only. |
Dosing figures reflect published literature and commonly reported community protocols. They are informational only.
Head-to-head comparisons
Each comparison below is its own page with the full attribute table, key differences and shared attributes for that pairing. They are grouped by the category the compounds are indexed under.
GLP-1 receptor agonists
Direct comparisons between the incretin-based compounds most often searched against one another.
Metabolic and GLP-1 compounds
Compounds indexed under metabolic use, including the GLP-1 receptor agonists and the smaller fat-metabolism peptides often searched alongside them.
Recovery and tissue repair
Pairings between compounds indexed for healing, connective tissue and post-injury recovery.
Growth-hormone axis
Secretagogues and releasing peptides that act on growth-hormone signalling, compared with each other and with adjacent compounds.
Longevity and mitochondrial
Compounds indexed under longevity, cellular and mitochondrial function.
Sexual health
Melanocortin and related compounds indexed for sexual-health use.